Skip to main content
CYPH
NASDAQ Life Sciences

Winklevoss Affiliate Receives 43.3M Pre-Funded Warrants in $33.3M Asset Sale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.074
Mkt Cap
$115.308M
52W Low
$0.26
52W High
$3.7
52W Position info
313% above low
Off High info
71% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

CYPH has more than doubled off its 52-week low of $0.26 on elevated volume (2.7× avg).

Summary

Winklevoss affiliate received 43.3M pre-funded warrants as consideration for selling a Zcash mining fleet to Cypherpunk, and exercised 16.6M warrants for common shares.


Key Events · Ownership and Investor Activity · CYPH

  • Asset Sale Consideration

    Winklevoss Treasury Investments received 43,290,042 pre-funded warrants at $0.77 each, totaling $33,333,332, as consideration for selling certain assets to Cypherpunk.

  • Warrant Exercise

    The affiliate exercised 16,570,852 pre-funded warrants at $0.001 per share, acquiring 16,570,852 common shares and disposing of the warrants at $0.5196 each.

  • Ownership Stake

    Post-transaction, the Winklevoss group beneficially owns 102,167,808 shares, including 76,431,746 shares held indirectly through Winklevoss Treasury Investments.

  • Related-Party Transaction

    The asset purchase was disclosed in an 8-K filed 2026-08-18; this Form 4 provides the specific warrant terms and exercise details.


Analysis · CYPH · Life Sciences

The Form 4 details the consideration for the previously announced acquisition of a Zcash mining fleet from a Winklevoss affiliate. The affiliate received 43.3 million pre-funded warrants valued at $33.3 million, and separately exercised 16.6 million warrants to acquire common shares. This clarifies the structure of the deal and the Winklevoss group's increased ownership stake, which now totals over 102 million shares. The transaction is significant relative to the company's market cap, but it is a related-party asset sale rather than an open-market purchase, so the signal is mixed.

At the time of this filing, CYPH was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.3M. The 52-week trading range was $0.26 to $3.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CYPH - Latest Insights

CYPH
Aug 18, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
CYPH
Aug 12, 2026, 7:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
CYPH
Aug 12, 2026, 7:14 AM EDT
Source: Reuters
Importance Score:
8
CYPH
Aug 12, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
CYPH
Jul 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9